Nurix Therapeutics, Inc. - Common stock (NRIX)
NRIX moved a median of -0.12% 30 minutes after news, and +0.33% by the close. How NRIX actually reacts to news — the realized, point-in-time move the market made, measured across 391 labeled events over the last three years with zero look-ahead.
NRIX’s median reaction, across the day.
| Horizon | Median | % positive | Events |
|---|---|---|---|
| 5-min | +0.38% | 57% | 391 |
| 30-min | -0.12% | 46% | 391 |
| 60-min | -0.28% | 46% | 391 |
| to close | +0.33% | 52% | 391 |
| Middle 50% of NRIX reactions | -1.47% to +1.39% |
|---|---|
| Median reaction (30-min) | -0.12% |
| Measured reactions | 391 |
Half of all Nurix Therapeutics, Inc. - Common stock news events land between -1.47% and +1.39% at 30 minutes.
Reaction stats as of 2026-09-21. Newest measured event . Reaction = percent move vs. the price at the news timestamp.
How NRIX reacts, by analyst action.
| Event | Events | Median 30-min | % positive | Median to close |
|---|---|---|---|---|
| Coverage initiations | 28 | +0.34% | 57% | +1.16% |
| Rating reiterations | 150 | -0.07% | 49% | -0.33% |
| Price-target raises | 27 | -0.51% | 37% | -0.29% |
| Price-target cuts | 20 | +0.31% | 60% | +0.41% |
Last 3 years, pulled 2026-09-21. Reaction = percent move vs. the price at the news timestamp. Counts and medians only. The same measurement runs across every name in the dataset. 2 further classes were observed with fewer than 10 measured events and are not published. See how NRIX ranks against every other measured name →
That’s how NRIX usually reacts — get an email when it moves on news →Email me when NRIX moves on news.
One email per qualifying move — the headline, the measured reaction, and how it compares to NRIX's baseline. Nothing else.
Recent NRIX events, each with its measured reaction.
| Date | Headline | Event | Source | 5-min | To close |
|---|---|---|---|---|---|
| Form 10-Q Nurix Therapeutics, Inc. For: Aug 31 | SEC filing · Form 10-Q | SEC EDGAR | +0.68% | -0.14% | |
| Form 8-K Nurix Therapeutics, Inc. For: Oct 12 | SEC filing · Form 8-K | SEC EDGAR | +0.68% | -0.14% | |
| Nurix Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | +0.68% | -0.14% | |
| Nurix Therapeutics Announces First Patient Enrolled in Phase 1b/2 Combination Study of Bexobrutideg in Chronic Lymphocytic Leukemia | Press release | GlobeNewswire | -0.87% | +1.34% | |
| Nurix Therapeutics Announces Second Research Term Extension for Oncology Program Under Collaboration with Gilead Sciences | Press release | GlobeNewswire | +0.30% | +0.31% | |
| Nurix Therapeutics Announces Achievement of $7 Million Milestone Under Strategic Collaboration with Pfizer | Press release | GlobeNewswire | -0.23% | +0.45% | |
| Nurix Therapeutics to Participate in Upcoming September Investor Conferences | Press release | GlobeNewswire | +1.02% | +2.24% | |
| Nurix Therapeutics Announces Appointment of Wes Burwell as Chief Human Resources Officer | Press release | GlobeNewswire | +0.82% | -1.02% | |
| Nurix Announces $10 Million Milestone Payment Associated with Initiation of a Phase 1 Clinical Trial of a STAT6 Degrader | Press release | GlobeNewswire | -1.56% | +4.18% | |
| Nurix Therapeutics Announces First Patient Enrolled in Registrational Phase 3 DAYBreak CLL-306 Trial of Bexobrutideg in Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma | Press release | GlobeNewswire | -1.56% | +4.18% | |
| Nurix Therapeutics Announces HSR Clearance of Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology | Press release | GlobeNewswire | -0.15% | -0.63% | |
| Form 10-Q Nurix Therapeutics, Inc. For: May 31 | SEC filing · Form 10-Q | SEC EDGAR | -4.26% | -7.24% | |
| Form 8-K Nurix Therapeutics, Inc. For: Jul 09 | SEC filing · Form 8-K | SEC EDGAR | -4.26% | -7.24% | |
| Nurix Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update | Press release | GlobeNewswire | -4.26% | -7.24% | |
| Form 8-K Nurix Therapeutics, Inc. For: Jun 11 | SEC filing · Form 8-K | SEC EDGAR | +0.72% | +11.78% | |
| Nurix Therapeutics to Report Updated Phase 1a/b Results for BTK Degrader Bexobrutideg, Highlighting Durable Responses in Relapsed/Refractory CLL/SLL and Promising Activity in Earlier Lines of Therapy | Press release | GlobeNewswire | +0.72% | +11.78% | |
| Form 8-K Nurix Therapeutics, Inc. For: Jun 06 | SEC filing · Form 8-K | SEC EDGAR | +6.52% | -6.24% | |
| Nurix Therapeutics Announces Global Collaboration with Roche to Co-Develop and Co-Commercialize Potential Best-in-Class BTK Degrader Bexobrutideg Across Malignant Hematology, Immunology and Neurology | Press release | GlobeNewswire | +6.52% | -6.24% | |
| Form 8-K Nurix Therapeutics, Inc. For: May 15 | SEC filing · Form 8-K | SEC EDGAR | +1.57% | -2.51% | |
| Nurix Therapeutics Presents New Preclinical and Phase 1 Translational Data Supporting Bexobrutideg (NX-5948) in Chronic Spontaneous Urticaria at the 2026 Society for Investigative Dermatology Annual Meeting | Press release | GlobeNewswire | +0.25% | +0.47% | |
| Nurix Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | -0.58% | +1.38% | |
| Nurix Therapeutics Announces Bexobrutideg Oral Presentation at the 2026 European Hematology Association Congress | Press release | GlobeNewswire | -0.58% | +1.38% | |
| Nurix Therapeutics Announces New Preclinical Data Highlighting Breadth of Targeted Protein Degradation Pipeline at AACR 2026 | Press release | GlobeNewswire | -0.60% | +0.42% | |
| Form 10-Q Nurix Therapeutics, Inc. For: Feb 28 | SEC filing · Form 10-Q | SEC EDGAR | +1.18% | -5.85% | |
| Form 8-K Nurix Therapeutics, Inc. For: Apr 08 | SEC filing · Form 8-K | SEC EDGAR | +1.18% | -5.85% | |
| Nurix Therapeutics Reports First Quarter 2026 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | +1.18% | -5.85% | |
| Nurix Therapeutics to Participate in Upcoming Investor Conference | Press release | GlobeNewswire | -0.55% | +0.61% | |
| Form ARS Nurix Therapeutics, Inc. For: Nov 30 | SEC filing · Form ARS | SEC EDGAR | +0.13% | -3.84% | |
| Form DEF 14A Nurix Therapeutics, Inc. For: May 15 | SEC filing · Form DEF | SEC EDGAR | +0.13% | -3.84% | |
| Form DEFA14A Nurix Therapeutics, Inc. | SEC filing · Form DEFA14A | SEC EDGAR | +0.13% | -3.84% | |
| Nurix Therapeutics Announces Multiple Presentations Showcasing Depth of Research Pipeline and Scientific Leadership at the American Association for Cancer Research (AACR) 2026 Annual Meeting | Press release | GlobeNewswire | +0.41% | -0.55% | |
| Form 8-K Nurix Therapeutics, Inc. For: Mar 06 | SEC filing · Form 8-K | SEC EDGAR | +3.71% | +4.66% | |
| Form 10-K Nurix Therapeutics, Inc. For: Nov 30 | SEC filing · Form 10-K | SEC EDGAR | +1.64% | -3.62% | |
| Form 8-K Nurix Therapeutics, Inc. For: Jan 28 | SEC filing · Form 8-K | SEC EDGAR | +1.64% | -3.62% | |
| Form S-8 Nurix Therapeutics, Inc. | SEC filing · Form S-8 | SEC EDGAR | +1.64% | -3.62% | |
| Nurix Therapeutics Reports Fourth Quarter and Fiscal Year 2025 Financial Results and Provides a Corporate Update | Press release | GlobeNewswire | +1.64% | -3.62% | |
| Form 8-K Nurix Therapeutics, Inc. For: Jan 12 | SEC filing · Form 8-K | SEC EDGAR | -1.04% | -3.92% | |
| Nurix Therapeutics Outlines 2026 Goals and Objectives for Advancing Bexobrutideg and Its Pipeline of Novel Degrader-Based Medicines in Cancer and Autoimmune Diseases | Press release | GlobeNewswire | -1.04% | -3.92% | |
| Nurix Therapeutics to Participate in the 44th Annual J.P. Morgan Healthcare Conference | Press release | GlobeNewswire | -1.11% | -3.16% | |
| Form 8-K Nurix Therapeutics, Inc. For: Dec 06 | SEC filing · Form 8-K | SEC EDGAR | +1.75% | -8.77% | |
| Nurix Therapeutics Presents New Data from the Phase 1 Trial of Bexobrutideg (NX-5948) in Waldenström Macroglobulinemia at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition | Press release | GlobeNewswire | +2.76% | +0.33% | |
| Nurix Therapeutics Presents New Data Demonstrating Durable, Deepening Responses in Phase 1 Trial of Bexobrutideg (NX-5948) in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) at the 67th American Society of Hematology (ASH) Annual M | Press release | GlobeNewswire | +2.76% | +0.33% | |
| Nurix Therapeutics Announces Webcast to Review New and Updated Data from the Phase 1 Clinical Trial of BTK Degrader Bexobrutideg (NX-5948) To Be Presented at the 67th American Society of Hematology (ASH) Annual Meeting and Exposition | Press release | GlobeNewswire | +1.28% | -1.74% | |
| Nurix Therapeutics to Participate in the Piper Sandler 37th Annual Healthcare Conference | Press release | GlobeNewswire | +1.34% | -0.70% | |
| Form 8-K Nurix Therapeutics, Inc. For: Nov 06 | SEC filing · Form 8-K | SEC EDGAR | +0.59% | -2.93% | |
| Nurix Therapeutics Appoints Accomplished Biopharmaceutical Leader Roger Dansey, M.D., to Its Board of Directors | Press release | GlobeNewswire | +0.59% | -2.93% | |
| Nurix Therapeutics Presents New Translational Data from First-in-Human Clinical Trial of Oral CBL-B Inhibitor NX-1607 Demonstrating Immune Activation and Tumor Microenvironment Remodeling | Press release | GlobeNewswire | -0.89% | -0.32% | |
| Nurix Therapeutics Announces Presentations at the 67th American Society of Hematology (ASH) Annual Meeting | Press release | GlobeNewswire | +1.93% | -0.79% | |
| Nurix Therapeutics to Participate in Upcoming Investor Conferences | Press release | GlobeNewswire | +1.77% | +10.17% | |
| Nurix Therapeutics Announces Closing of $250.0 Million Registered Offering of Common Stock | Press release | GlobeNewswire | +3.88% | +6.87% |
Each reaction is the move the market actually made, measured from the news timestamp. Headlines link through to the NRIX section they belong to.
Where else NRIX is measured.
NRIX earnings → · Analyst actions → · SEC filings →
Every ticker we measure the same way24
Apple (AAPL)
How AAPL actually reacts to news, measured.
NVIDIA (NVDA)
How NVDA actually reacts to news, measured.
Tesla (TSLA)
How TSLA actually reacts to news, measured.
Microsoft (MSFT)
How MSFT actually reacts to news, measured.
Advanced Micro Devices (AMD)
How AMD actually reacts to news, measured.
Amazon (AMZN)
How AMZN actually reacts to news, measured.
Alphabet (GOOG)
How GOOG actually reacts to news, measured.
Meta Platforms (META)
How META actually reacts to news, measured.
Broadcom (AVGO)
How AVGO actually reacts to news, measured.
JPMorgan Chase (JPM)
How JPM actually reacts to news, measured.
Visa (V)
How V actually reacts to news, measured.
Walmart (WMT)
How WMT actually reacts to news, measured.
Eli Lilly (LLY)
How LLY actually reacts to news, measured.
UnitedHealth Group (UNH)
How UNH actually reacts to news, measured.
Netflix (NFLX)
How NFLX actually reacts to news, measured.
Johnson & Johnson (JNJ)
How JNJ actually reacts to news, measured.
Exxon Mobil (XOM)
How XOM actually reacts to news, measured.
Home Depot (HD)
How HD actually reacts to news, measured.
Costco (COST)
How COST actually reacts to news, measured.
Mastercard (MA)
How MA actually reacts to news, measured.
Oracle (ORCL)
How ORCL actually reacts to news, measured.
Salesforce (CRM)
How CRM actually reacts to news, measured.
Bank of America (BAC)
How BAC actually reacts to news, measured.
Coca-Cola (KO)
How KO actually reacts to news, measured.
Walt Disney (DIS)
How DIS actually reacts to news, measured.
Browse all tickers
Every name we’ve measured, in one place.
How the numbers are made.
How is Nurix Therapeutics, Inc. - Common stock's median reaction calculated?
Every labeled NRIX news event is measured from its own timestamp: the last trade before the news is the base price, and the move is read at fixed horizons — 30 minutes of trading, then the close. The median across 391 events is what this page reports. Point-in-time, zero look-ahead: no event borrows information from a later one.
What counts as a positive reaction?
Any event whose price move is above zero at the horizon, relative to the last trade before the news timestamp. 46% of NRIX's measured events are up at 30 minutes; the rest close the window flat or negative.
How often is this page updated?
The news table refreshes automatically as new events are labeled and priced. The reaction medians are re-pulled in batches from the dataset — the figures here are as of 2026-09-21.
Does NRIX's past reaction predict its next one?
No. These are realized facts about past events, not forecasts. They describe a distribution — they say nothing certain about any future move.